| Is combination therapy an effective way of reaching lipid goals in Type 2 diabetes mellitus? | |
| | |
MedLine Citation:
|
PMID: 22142158 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Type 2 diabetes mellitus is associated with a specific pattern of plasma lipid and lipoprotein abnormalities. Lipid goals are often not attained with statins alone, and combination lipid-lowering strategies may need to be considered in an attempt to further reduce the residual cardiovascular risk. Combination therapy utilizes various classes of lipid-lowering medications with different mechanisms of action and different effects on lipid levels. Clinical trial data support the efficacy of combining statins with fibrates, niacin, ezetimibe (cholesterol absorption inhibitor) and colesevelam (bile acid sequestrant) with the caveat that there are insufficient clinical trial data to show a further robust benefit on cardiovascular outcomes. Of the different combination therapy options to potentiate low-density lipoprotein cholesterol lowering in combination with a statin, colesevelam provides additional beneficial effects by further reducing hemoglobin A1c levels in Type 2 diabetes mellitus. |
| | |
Authors:
|
Yehuda Handelsman; Vivian Fonseca; Julio Rosenstock |
Related Documents
:
|
15210698 - Mycobacterium tuberculosis reprograms waves of phosphatidylinositol 3-phosphate on phag... 2253028 - The ontogeny of feline temporal lobe epilepsy: kindling a spontaneous seizure disorder ... 21426238 - Combination therapy with statin and fibrate in patients with dyslipidemia associated wi... 9770318 - The assessment of menstrual synchrony: comment on weller and weller (1997) 686438 - Glucose transport across the rat blood-brain barrier during anesthesia. 312198 - The leucocyte migration inhibition test and subpopulations of peripheral lymphocytes in... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Expert review of clinical pharmacology Volume: 5 ISSN: 1751-2441 ISO Abbreviation: Expert Rev Clin Pharmacol Publication Date: 2012 Jan |
Date Detail:
|
Created Date: 2011-12-06 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101278296 Medline TA: Expert Rev Clin Pharmacol Country: England |
Other Details:
|
Languages: eng Pagination: 43-54 Citation Subset: IM |
Affiliation:
|
Metabolic Institute of America, 18372 Clark Street, Suite #212, Tarzana, CA 91356, USA. yhandelsman@pacbell.net. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Potential drug interactions associated with treatments for Type 2 diabetes and its comorbidities: a ...
Next Document: Diabetic macular edema: new trends in management.